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Abstract
Background: Non Hodgkin lymphomas are the most common lymphomas in Uganda. Recent studies
from developed countries have shown differences in survival for the different immunophenotypes. Such
studies are lacking in Africa where diagnosis is largely dependent on morphology alone. We report
immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients in Kampala,
Uganda.
Methods: Non Hodgkin lymphoma tissue blocks from the archives of the Department of Pathology,
Makerere University College of Health Sciences, Kampala, Uganda, from 1991-2000, were sub typed using
haematoxylin and eosin, Giemsa as well as immunohistochemistry. Using tissue micro array, 119 biopsies
were subjected to: CD3, CD5, CD10, CD20, CD23, CD30, CD38, CD79a, CD138, Bcl-6, Bcl-2, IRTA-1,
MUM1/IRF4, Bcl-1/cyclin D1, TdT, ALKc, and Ki-67/Mib1. Case notes were retrieved for: disease stage,
chemotherapy courses received and retrospective follow up was done for survival.
Results: Non Hodgkin B cell lymphomas comprised of Burkitt lymphoma [BL] (95/119) diffuse large B cell
lymphoma (19/119), mantle cell lymphoma (4/119) and precursor B lymphoblastic lymphoma (1/119).
For Burkitt lymphoma, good prognosis was associated with receiving chemotherapy, female gender and
CD30 positivity. Only receiving chemotherapy remained significant after Cox regression analysis. Diffuse
large B cell lymphomas with activated germinal centre B cell (GCB) pattern (CD10+/-, BCL-6+/-, MUM+/
-, CD138+/-) had better survival (98.4 months; 95% CI 89.5 -107.3) than the others (57.3 months; 95% CI
35.5 - 79.0) p = 0.027 (log rank test).
Conclusions: Activated GCB diffuse large B cell lymphoma had a better prognosis than the others. For
Burkitt lymphoma, not receiving chemotherapy carried a poor prognosis. Availability of chemotherapy in
this resource limited setting is critical for survival of lymphoma patients.
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Background
Non Hodgkin B cell lymphomas are heterogeneous in
morphology, immunophenotype and response to ther-
apy. Recent studies have shown differences in survival
based on their molecular profile[1].
In developing countries, clinically aggressive subtypes
such as Burkitt and diffuse large B cell lymphoma pre-
dominate and, unfortunately, result in poor outcome[2].
Factors that influence survival in non Hodgkin lympho-
mas in resource poor settings include socio economic sta-
tus, stage of disease at presentation and getting a full
course of treatment. In Uganda, several studies have
described clinical factors associated with outcome of
Burkitt lymphoma [3,4].
In the developed countries, several methods including
gene profiling and immunohistochemistry have been
used for predicting prognosis [5,6]. Using the gene expres-
sion profile of germinal centre B and activated B cell, dif-
fuse large B cell lymphoma (DLBCL) was subdivided into
3 prognostic groups. However, there are several draw
backs of gene expression profiling especially in resource
constrained countries such as Uganda. It requires the use
of optimally cryopreserved or fresh tissues as well as DNA
micro array technology which is more costly than immu-
nohistochemistry on paraffin sections.
Recently, several workers have used germinal centre and
activated B cell immunohistochemical markers on paraf-
fin embedded tissue blocks to classify DLBCL into three
prognostic groups[7,8].
These include: (a) activated non GCB (CD10-, Bcl-6-,
MUM1/IRF4 ±, CD138+); (b)activated GCB (CD10+, Bcl-
6+, MUM1/IRF4 ±, CD138+); and (c) non activated GCB
(CD10+, Bcl-6+, MUM1/IRF4-, CD138-). They showed
that patients with a germinal centre B cell profile have a
much better prognosis than those with the activated B cell
type. Such studies have hitherto not been carried out in
Uganda. We report immunohistochemical and other
prognostic factors in B cell non Hodgkin lymphoma
patients in Kampala, Uganda
Methods
Study design and sampling
A cross sectional descriptive design was used for lym-
phoma diagnosis and immunophenotyping, while a ret-
rospective cohort was used to determine survival. For the
cross sectional study, haematoxylin and eosin and Giemsa
staining was carried out in the Department of Pathology,
Makerere University and immunohistochemistry in the
Unit of Hematopathology, Institute of Hematology and
Clinical Oncology "L. & A. Seràgnoli", Bologna University
School of Medicine, Bologna, Italy. One hundred and
twenty nine patients' biopsies diagnosed between 1991-
2000 as non Hodgkin lymphoma were sub typed using
tissue microarray (TMA) and immunohistochemistry with
CD3, CD5, CD10, CD20, CD23, CD30, CD38, CD79a,
CD138, Bcl-6, Bcl-2, IRTA-1, MUM1/IRF4, Bcl-1/cyclin
D1, TdT, ALKc, and Ki-67/Mib1.
For the retrospective cohort study we retrieved patients'
case notes from the Uganda Cancer Institute in order to
obtain details of the patients' disease stage, type of chem-
otherapy, number of courses received, whether dead or
alive, time to death. Cancer registry data was also used
when the addresses of the patients fell within Kyadondo
County, the area covered by the Kampala Cancer Registry.
One of us (LKT) and two research assistants followed up
patients whose survival status was not clear. The follow up
involved tracing patients to their homes (district, sub-
county, parish and village) in the different regions of
Uganda.
The patients had been treated at the Uganda Cancer Insti-
tute which is the oldest unit for cancer treatment in the
country. It began as a centre for the treatment of Burkitt
lymphoma patients in the 1960s and has two units: the
solid tumor treatment unit and the lymphoma treatment
centre. Those with Burkitt lymphoma received COM[9]
(cyclophosphamide, vincristine, intrathecal methotrex-
ate) whereas those with other non Hodgkin lymphomas
received CHOP (cyclophosphamide, adriamycin, vincris-
tine and prednisolone).
Tissue micro array construction (TMA)
Haematoxylin and eosin (H&E) stained slides were used
to identify the representative tumor fields that were
marked and correspondingly identified on the tissue
blocks.
Tissue cylinders of diameter of 1 mm were punched from
the marked areas on each block and incorporated into a
recipient paraffin block using a precision instrument, the
tissue arrayer (Beecher Instruments, Silver Spring, Mary-
land, USA). For adequate sampling each specimen was
represented in duplicate using 1 mm cores in the recipient
block. Three TMA recipient blocks were made; two of
these had 48 punches each of Burkitt lymphoma while the
other one had 33 punches of other non Hodgkin lympho-
mas.
Immunohistochemistry
Four-μm thick sections were cut from TMAs, coated on
electrically charged slides, re-hydrated, and submitted to
antigen retrieval in ethylene diamine tetra acetic acid
(EDTA) 1 mM (pH 8.0) by micro-waving twice for 5 min-
utes at either 750 or 900 W, that was very efficient accord-
ing to previous experience[10].BMC Clinical Pathology 2009, 9:11 http://www.biomedcentral.com/1472-6890/9/11
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After cooling, the slides were put on a TechMate 500
immunostainer and incubated for 30 minutes at room
temperature with antibodies against CD3, CD5, CD10,
CD20, CD23, CD30, CD38, CD79a, CD138, Bcl-6, Bcl-2,
IRTA-1, MUM1/IRF4, Bcl-1/cyclin D1, TdT, ALKc, and Ki-
67/Mib1. Details on the antibodies, sources, dilutions
and antigen retrieval are listed in Table 1.
The antibodies were detected by either the alkaline phos-
phatase anti-alkaline phosphatase immunocomplexes
(APAAP) technique or the Envision+ technique [11].
Data management, analysis and statistical issues
For the descriptive cross sectional study, a sample size of
112 was calculated using a formula by Kish and Les-
lie[12]. In this calculation we assumed that the prevalence
of B cell non Hodgkin's lymphoma in the total popula-
tion of non-Hodgkin lymphoma was 92.1% according to
a Ugandan study[2] with a precision of 5% and 95% con-
fidence interval.
For the retrospective cohort design, a sample size of 52
was calculated using a formula by Fleiss with 80% power
and 95% confidence interval [12]. We assumed the
expected outcome among patients with NHL of germinal
centre origin would be 86% and the expected outcome
among patients with NHL of non germinal centre origin
would be 63%.
Data was collected and entered into the computer using
EPI INFO software (supplied by CDC and WHO) for stor-
age and initial analysis. Further analysis was done using
Table 1: Primary antibodies used for the study.
Antibody Clone Source Antigen retrieval Dilution
CD3 SP7 Immunotech EDTA 750 W 1:250
CD5 54/F6 Dako EDTA 900 W 1:10
CD10 56C6 Novocastra EDTA 900 W 1:5
CD20 L26 Dako EDTA 750 W 1:200
CD23 1B12 Novocastra EDTA 900 W 1:30
CD30 Ber- H2 Prof. Falini * EDTA 900 W 1:3
CD38 SPC32 Novocastra EDTA 750 W 1:10
CD79a JCB117 Prof. Mason § EDTA 750 W 1:10
CD138 - Neomarkers EDTA 900 W 1:20
BCL-1 SP4 Neomarkers EDTA 900 W 1:20
BCL-6 PG-B6p Prof. Falini * EDTA 900 W Undiluted
BCL-2 124 Prof. Mason§ EDTA 900 W 1:3
IRTA-1 Mum2EC Prof. Falini * EDTA 900 W 1:2
MUM1/IRF4 - Prof. Falini * EDTA 900 W 1:2
TdT - Dako None 1:30
ALKc - Prof. Falini * EDTA 900 W 1:2
Ki-67 Mib-1 Dako EDTA 900 W 1:20
* Kindly provided by Prof. Brunangelo Falini, Perugia University, Perugia, Italy.
§Kindly provided by Prof. David Y. Mason, Oxford University, Oxford, before his premature death.BMC Clinical Pathology 2009, 9:11 http://www.biomedcentral.com/1472-6890/9/11
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SPSS software. For continuous variables, the relevant
measures of central tendency (means for normally distrib-
uted data and medians and inter-quartile ranges for
skewed data) were used to explore the data.
Kaplan-Meier curves and the log rank test were used to
determine survival. To determine factors associated with
overall survival, univariate and multivariate Cox hazards
regression analysis was carried out. A p value of less than
0.05 was considered significant.
Ethical issues
Permission to carry out the study was obtained from the
Makerere University Faculty of Medicine Research and
Ethics Committee.
Study limitations
This was a retrospective rather than prospective study
making it difficult to get good socio-demographic infor-
mation. Clinical outcome predictors such as the Interna-
tional prognostic Index were not complete. Lactate
dehydrogenase was not routinely done in the patients.
Results
Background characteristics
The median age was 9.0 (inter-quartile range 6- 15.5)
years. The youngest patient was 2 years and the oldest was
64 years. The mean age was 15.7 (SD 15.5) years.
As expected, 79.8% of the patients had Burkitt lymphoma,
followed by diffuse large B cell lymphoma (16.0%), man-
tle cell lymphoma (3.4%), and precursor B lymphoblastic
lymphoma (0.8%) (Table 2)
Burkitt lymphoma survival
The male patients had a mean survival of 3.3 (95% CI
0.81-5.8) months while the females had a mean survival
of 17.7 (95% CI 8.3-27.0) months, p = 0.028. The CD30
negative patients had a mean survival of 6.8 (95% CI 0.0
- 14.7) while the CD30 positive had a mean survival of
12.3 (95% CI 7.3 - 17.3), p = 0.0169.
Only receiving chemotherapy remained significant after
Cox regression analysis (Table 3)
Burkitt lymphoma survival by EBER status
Overall 97.3% were EBER positive. Survival information
was available on 25 patients whose EBER results were
available. Of these, 24 (96%) were EBER positive. The
mean survival for the 24 was 9.28(95%CI 3.27-15.29
months). However there was only one EBER negative
patient whose survival was 1.2 months.
Burkitt lymphoma: EBER status and CD30 positivity
A total of 55 cases had both CD30 and EBER results. Of
the 24 CD30 positive, 23(95.8%) were EBER positive. Of
the 31 CD30 negative, 30(96.8%) were EBER positive.
The difference was not statistically significant (p = 0.83);
and because of this, the EBER result was not entered into
Cox regression analysis.
Diffuse large B cell lymphoma survival
Diffuse large B cell lymphomas with activated germinal
centre B cell (GCB) pattern (CD10+/-, BCL-6+/-, MUM+/-
, CD138+/-) had better survival (98.4 months; 95% CI
89.5 -107.3) than the others (57.3 months; 95% CI 35.5 -
79.0) p = 0.027 (log rank test) (Figure 1)
Table 2: Distribution of B cell non Hodgkin lymphoma by diagnosis and immunophenotype
Diagnosis
Marker Burkitt
lymphoma
(%positive)
Diffuse large B cell lymphoma 
(% positive)
Precursor B lymphoblastic 
lymphoma
Mantle cell lymphoma
CD10 74/79(93.7) 3/18 (16.7) 1/1 0/4
CD20 95/95(100) 19/19(100) 1/1 4/4
BCL6 46/69(66.7) 2/19(10.5) 0/1 1/4
CD79a 48/68(70.6) 6/16(37.5) 1/1 2/4
CD38 35/68(51.5) 3/16(18.8) 0/1 0/4
MUM-1/IRF4 1/77(1.3) 4/18(22.2) 0/1 0/4
EBER 79/86(91.9) 6/17(35.3) 1/1 0/4
Tdt 0/95(0) 0/19(0) 1/1 0/4
BCL2 6/79(7.6) 7/19(36.8) 1/1 4/4
CD3 0/86(0) 0/19(0) 0/1 0/3
CD138 43/95(45.3) 10/15(66.7) 0/1 4/4
CD30 35/95(36.8) 2/17(11.8) 0/1 0/4BMC Clinical Pathology 2009, 9:11 http://www.biomedcentral.com/1472-6890/9/11
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Discussion
The aim of this paper was to classify B cell non Hodgkin
lymphomas in Uganda using immunohistochemical
markers and correlate this and other factors to patient out-
come.
In the current study, B cell non Hodgkin lymphomas seem
to be affecting mainly young people, with a median age of
9 years. The mean age was 15.7 years consistent with
results of previous similar studies from Uganda [2], but
much lower than that reported from Kenya by Cool and
Bitter [13].
Table 3: Results of Cox regression analysis for survival, Burkitt 
lymphoma cases, Uganda
Variable Hazard's ratio (95.0% CI) p value
Received chemotherapy 0.15 (0.001-0.195) 0.001
CD30 0.427 (0.098-1.863) 0.257
Male 4.207 (0.775-22.84) 0.096
CI Confidence Intervals
Kaplan Meier survival curve for patients with Diffuse Large B Cell Lymphoma, Kampala, Uganda Figure 1
Kaplan Meier survival curve for patients with Diffuse Large B Cell Lymphoma, Kampala, Uganda.BMC Clinical Pathology 2009, 9:11 http://www.biomedcentral.com/1472-6890/9/11
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Overall survival of patients with B cell non Hodgkin 
lymphomas
Burkitt lymphoma
The overall survival of patients with B cell non Hodgkin
lymphomas was 60 months but only 12.7 months in
patients with Burkitt lymphoma. This survival of patients
with Burkitt lymphoma in this series is surprisingly much
lower than what was reported from the same centre in the
1970s and 1980s by Olweny and others [14]. This differ-
ence could possibly be due to the fact that Olweny's stud-
ies were done on a cohort that was meticulously followed
up, unlike the current investigation in which we studied
routine patients who came to the Uganda Cancer Institute
for treatment and who were not particularly followed up
or sought after to complete treatment [14].
In the current study factors associated with better survival
included receiving chemotherapy, female gender and
CD30 positivity.
As expected those who did not receive chemotherapy died
within the first month after presentation to hospital. The
possible reason for this is that the Uganda Cancer institute
is grossly under funded and therefore patients have to buy
anticancer drugs from private pharmacies. Unfortunately,
most patients are poor and therefore cannot afford the
drugs[15]. Many patients are referred from rural areas to
the main cancer treatment centre in Kampala at the
Uganda Cancer Institute and this constitutes further delay.
In Uganda, the standard regimen for treating Burkitt lym-
phoma is cyclophosphamide, vincristine, prednisolone
(COM) and intrathecal methotrexate for central nervous
system disease prophylaxis [9,14]. In our study, those
who received chemotherapy with COM had a better over-
all survival than those who did not. Endemic Burkitt lym-
phoma is characterised by a very high proliferative index
nearing 100%, and the disease is very rapidly progressive
with a doubling time of 24 hours and is fatal if not treated
early with intensive chemotherapy regimens [16].
Another factor associated with poor survival was male
gender. Similar observations have been made by other
authors in studies on childhood cancers [17,18]. The rea-
sons for the difference in prognosis between males and
females among patients with Burkitt lymphoma are not
very clear. However, one explanation is that males have an
inherent tendency to have higher rates of cell division
than females [19]. The fact that the growth rate of the
male embryo is higher than that of the female [20] has
been suggested as lending credence to this hypothesis
[21].
Of interest in our study was the high CD30 positivity
(37%) in Burkitt lymphoma.
This is different from results of a previous study in the
United Kingdom where CD30 positivity in Burkitt lym-
phoma patients was not so high: Jones and others found
18% (3/17) CD30 positivity in childhood Burkitt lym-
phoma in the West Midlands, UK [22,23].
In our study CD30 positive patients had a better survival
than those who were CD30 negative. Previously, CD30
positivity has not been associated with good prognosis in
Burkitt lymphoma [24]. Several authors have suggested
that the CD30-CD30L (ligand) interaction may have a
role in some non Hodgkin lymphomas including Burkitt
lymphoma [23,25]. Kanavaros et al 1992 found that
many CD30 positive non Hodgkin lymphomas were EBV
positive [25].
In our patients, CD30 positivity was found among those
with both "typical morphology and plasmacytoid fea-
tures." [2]. As we noted previously, this might be related
to the "postulated complex pathogenesis of BL" in Africa
[26]. Of interest is the multistep oncogenetic mechanism
(proposed by Klein [27]) "in which there is de-regulation
of MYC gene and subsequent development of a malignant
clone." However, it appears that more studies are needed
to shed more light on the specific role of CD30 in Burkitt
lymphomas.
Survival of patients with DLBCL
In our study, diffuse large B cell lymphomas fell into three
distinct groups with independent prognostic significance.
These included: (a) non activated GCB, (b) activated GCB,
and (c) activated non GCB. These are similar to the groups
identified by researchers in the developed countries [7].
Whereas studies in the developed countries have found
that non activated GCB had the best prognosis [7], in our
study we have found that patients with activated germinal
centre B- cell lymphoma had the best prognosis. The rea-
sons for this difference are not clear and given the small
numbers will have to be confirmed by larger studies. The
difference could also be a reflection of yet unrecognized
molecular heterogeneity in the tumors [28].
The overall survival of the patients with DLBCL in our
study was lower than that reported from the developed
countries. This could be related to the fact that in Uganda,
patients with DLBCL are treated with cyclophosphamide,
adriamycin, vincristine, prednisolone (CHOP) rather
than the more effective cyclophosphamide, adriamycin,
vincristine, prednisolone plus Rituximab (CHOP-R) that
has become the standard of care in the developed coun-
tries [29].BMC Clinical Pathology 2009, 9:11 http://www.biomedcentral.com/1472-6890/9/11
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Conclusion
Immunohistochemistry on paraffin embedded tissue
blocks using selected GCB and activation markers has
yielded important information that predicts the outcome
of patients with non Hodgkin B cell lymphomas in
Uganda. Generally the Ugandan patients studied had a
very poor prognosis. A number of factors including lack of
timely chemotherapy seem to be responsible for this.
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